<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04057794</url>
  </required_header>
  <id_info>
    <org_study_id>PDGene-01</org_study_id>
    <nct_id>NCT04057794</nct_id>
  </id_info>
  <brief_title>PDGeneration: Mapping the Future of Parkinson's Disease</brief_title>
  <acronym>PDGENE</acronym>
  <official_title>Parkinson's Foundation: PD Generation: Mapping the Future of Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parkinson's Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester - CHeT/CTCC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fulgent Laboratories</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Parkinson Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Parkinson's Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the feasibility, impact, and participant satisfaction of offering Clinical
      Laboratory Improvement Amendments (CLIA) certified genetic testing as part of clinical care
      for People with Parkinson's disease (PWP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate how offering Clinical Laboratory Improvement
      Amendments (CLIA) certified genetic testing for Parkinson's Disease (PD) genes to people with
      Parkinson's Disease impacts clinical care and potential enrollment in clinical trials. This
      study will be a longitudinal, multi-center study to evaluate how providing CLIA-certified
      genetic testing and genetic counseling by the Parkinson's Foundation for PD-related genes
      impacts people with Parkinson's lives, their clinical care, and knowledge of the PD genetics.
      The will also assess the impact of the mode of genetic counseling by comparing counseling
      conducted by a clinician in-person versus genetic counseling conducted through telephone.
      Knowledge of genetic status may have significant implications on clinical care, potential
      treatment options, and may provide insight on the rate of disease and PD prognosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2019</start_date>
  <completion_date type="Anticipated">April 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All participants will undergo genetic counseling service post-genetic testing either locally or through central services.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility Outcome</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To provide satisfactory counseling via two different modes of counseling, either by phone from genetic counselors or at an on-site meeting with a clinician/physician, to participants with Parkinson's thereby assessing participants level of satisfaction of said counseling by returned survey response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>The impact of knowledge gained by people with Parkinson's by assessing returned survey responses regarding their behavior and follow-up to clinical care after receipt of genetic counseling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Differences in satisfaction of receiving counseling by provider (genetic counselor vs. site clinician/physician) by returned survey responses of providers of Parkinson's care and participants with Parkinson's.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ready to enroll in precision medicine trials</measure>
    <time_frame>up to 12 months</time_frame>
    <description>number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time</measure>
    <time_frame>up to 12 months</time_frame>
    <description>comparison of first contact to return of results</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Parkinson's Disease and Parkinsonism</condition>
  <arm_group>
    <arm_group_label>On-Site Genetic Counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this part of the study will receive Counseling for genetic results.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telephone Genetic Counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to this part of the study will receive Counseling for genetic results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lab Assay for seven genetic variants for Parkinson's Disease</intervention_name>
    <description>Counseling provided to participant by an in-person visit by site clinician/physician</description>
    <arm_group_label>On-Site Genetic Counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lab Assay for seven genetic variants for Parkinson's Disease</intervention_name>
    <description>Counseling provided to participant by telephone from Genetic Specialists from Indiana University</description>
    <arm_group_label>Telephone Genetic Counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's
             Disease: probable diagnosis.

             2. Willingness to undergo genetic testing, and choose to be informed of genetic
             testing results for Glucosylceramidase Beta (GBA), LRRK2 and 5 additional PD related
             genes (SNCA, VPS35, PRKN, PINK-1, PARK7).

             3. Capacity to give full informed consent in writing, and have read and signed the
             informed consent forms (ICFs) based on clinician's determination.

             4. Able to perform study activities (including completion of either online, in-person
             or paper surveys).

             5. Individuals must speak and understand the English language.

        Exclusion Criteria:

          -  1. Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy,
             progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome),
             including that due to medications, metabolic disorders, encephalitis, cerebrovascular
             disease, or normal pressure hydrocephalus.

             2. Individuals who have received a blood transfusion within the past 3 months. 3.
             Individuals who have active hematologic malignancies such as lymphoma or leukemia.

             4. Individuals who have had a bone marrow transplant within the past 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy N Alcalay, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth U Lyda, BS</last_name>
    <phone>585-273-4038</phone>
    <email>elizabeth.lyda@chet.rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen C Hodgeman</last_name>
    <phone>585-273-5365</phone>
    <email>karen.hodgeman@chet.rochester.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Diego (UCSD)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Damron</last_name>
      <phone>858-822-5873</phone>
      <email>ldamron@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Irene Litvan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Williams</last_name>
      <phone>312-503-5645</phone>
      <email>k-williams8@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Max Galarce</last_name>
      <phone>312-503-4270</phone>
      <email>max.galarce@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tanya Simuni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remy Johnson</last_name>
      <phone>617-726-4936</phone>
      <email>rhjohnson@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mansi Sharma</last_name>
      <phone>508-395-3479</phone>
      <email>msharma13@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anne-Marie Wills, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Schwartzschild, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ann Hunt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albert Hung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Herrington, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grace Bwala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Partners/Park Nicollet: Struthers Parkinson's Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Rohde</last_name>
      <phone>952-993-5903</phone>
      <email>cindy.rohde@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Martha Nance, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Chan</last_name>
      <phone>212-305-4233</phone>
      <email>akc2177@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Roy Alcalay, MD, MSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oren Levy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hiral Shah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nora Vanegas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linn Katus, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jill Goldman, CGC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Park</last_name>
      <phone>215-829-5299</phone>
      <email>Jane.park@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Tropea, DO, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Siderowf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.parkinson.org/PDGENEration</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's</keyword>
  <keyword>Genetics</keyword>
  <keyword>PD Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

